Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum

Simply Wall St.11-09

Amylyx Pharmaceuticals (AMLX) stock has caught some attention recently, following several weeks of shifting trading patterns. Investors are keeping a close eye on the company as it navigates what has ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582864200?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2025-11-09 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582864200","market":"sg","top_or_hot":-1,"title":"Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>Amylyx Pharmaceuticals (AMLX) stock has caught some attention recently, following several weeks of shifting trading patterns. Investors are keeping a close eye on the company as it navigates what has ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-following-re\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-09 05:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-following-re><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amylyx Pharmaceuticals (AMLX) stock has caught some attention recently, following several weeks of shifting trading patterns. Investors are keeping a close eye on the company as it navigates what has ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-following-re\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMLX","symbol_name":"Amylyx Pharmaceuticals","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-following-re","article_id":"2582864200","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-following-re","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582864200","pubTimestamp":1762637622,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Amylyx Pharmaceuticals (AMLX) stock has caught some attention recently, following several weeks of shifting trading patterns. Investors are keeping a close eye on the company as it navigates what has been a volatile stretch for biotech shares.\nSee our latest analysis for Amylyx Pharmaceuticals.\nDespite a few turbulent days, Amylyx Pharmaceuticals' momentum over the past year has been impressive, with a 61% share price return in the last 90 days and a 214.8% year-to-date gain. Although the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMLX":"Amylyx Pharmaceuticals","BK4007":"制药"},"translate_title":"根据近期股价势头评估Amylyx Pharmaceuticals(AMLX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":1},"content_text":"Amylyx Pharmaceuticals (AMLX) stock has caught some attention recently, following several weeks of shifting trading patterns. Investors are keeping a close eye on the company as it navigates what has been a volatile stretch for biotech shares. See our latest analysis for Amylyx Pharmaceuticals. Despite a few turbulent days, Amylyx Pharmaceuticals' momentum over the past year has been impressive, with a 61% share price return in the last 90 days and a 214.8% year-to-date gain. Although the latest pullback reflects uncertainty after recent highs, its one-year total shareholder return of nearly 84% stands out, especially considering the stock’s considerably weaker three-year performance. If Amylyx’s dramatic rebound has you thinking about what is next in healthcare innovation, it is a great time to explore other opportunities with our See the full list for free. With Amylyx shares still trading well below analyst price targets despite major recent gains, the key question is whether the stock remains undervalued or if the market has already factored in all future prospects. AdvertisementPrice-to-Book Ratio of 4x: Is it justified? Amylyx Pharmaceuticals currently trades at a price-to-book ratio of 4x, significantly above both peer and industry averages. With the last close at $12.31, investors are right to ask if the market is overvaluing its future prospects or factoring in potential growth ahead of concrete results. The price-to-book ratio measures how much investors are paying for each dollar of net assets. In biotech, this multiple can be high for promising pipeline companies, but it should be justified by clear value creation or tangible progress toward profitability. Despite its rapid growth forecasts, Amylyx’s multiple is higher than both its immediate peer set average of 2.8x and the US Pharmaceuticals industry average of 2.3x. This considerable premium suggests an elevated expectation for future success, which may not be fully supported by trailing fundamentals. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book Ratio of 4x (OVERVALUED) However, ongoing net losses and the company’s high valuation compared to peers remain meaningful risks that could challenge the recent momentum in Amylyx shares. Find out about the key risks to this Amylyx Pharmaceuticals narrative.  Build Your Own Amylyx Pharmaceuticals Narrative If you see Amylyx’s story differently or want to walk through the numbers on your own terms, you can quickly build your own take in just a few minutes, Do it your way A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision. Looking for more investment ideas? Unlock fresh opportunities by searching beyond Amylyx. Don’t let the best stocks pass you by. Find others that match your ambitions with these top picks:  Tap into rapid growth by checking out these 24 AI penny stocks, which are set to benefit from artificial intelligence breakthroughs across multiple industries. Start building passive income streams with these 16 dividend stocks with yields > 3%, offering high yields while maintaining financial stability. Ride the next wave of technology by spotting future leaders among these 27 quantum computing stocks, powering advancements in computing and innovation.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582864200","isCrawlerRequest":true}